Losing a foot versus losing a dollar; a systematic review of cost studies in diabetic foot complications

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 17, Issue 2, 2017, Pages 165-180

  Petrakis, Ioannis ^a   Kyriopoulos, Ilias J ^a   Ginis, Alexandros ^b   Athanasakis, Kostas ^a  

^a NATIONAL SCHOOL OF PUBLIC HEALTH   (Greece)

^b Medical Department   (Greece)

Author keywords

Cost; diabetes; diabetic foot; expenditure; health care expenditure

Indexed keywords

ANTIBIOTIC AGENT; BECAPLERMIN; CLOSTRIDIOPEPTIDASE A; OXYGEN; SODIUM CHLORIDE;

ANTIBIOTIC THERAPY; ARTIFICIAL SKIN; AUSTRALIA; CANADA; COST OF ILLNESS; DEBRIDEMENT; DIABETIC FOOT; FOOT AMPUTATION; HEALTH CARE COST; HOSPITAL READMISSION; HOSPITALIZATION; HUMAN; HYPERBARIC OXYGEN THERAPY; LEG REVASCULARIZATION; LIMB SALVAGE; MORBIDITY; REIMBURSEMENT; REVIEW; SYSTEMATIC REVIEW; THROMBOCYTE RICH PLASMA; ULTRASOUND THERAPY; VACUUM ASSISTED CLOSURE; WOUND CARE; WOUND DRESSING; WOUND HEALING; AMPUTATION; DIABETES MELLITUS; ECONOMICS; PREVALENCE; STATISTICS AND NUMERICAL DATA;

AMPUTATION; COST OF ILLNESS; DIABETES MELLITUS; DIABETIC FOOT; HEALTH CARE COSTS; HOSPITALIZATION; HUMANS; PATIENT READMISSION; PREVALENCE;

EID: 85017415067     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1080/14737167.2017.1305891     Document Type: Review

References (76)

1. World Health Organization. Diabetes Key Facts. Available at http://www.who.int/mediacentre/factsheets/fs312/en/(Accessed on April 2016).
2. World Health Organization. Global Report on Diabetes. WHO, 2016. Available at http://apps.who.int/iris/bitstream/10665/204871/1/9789241565257_eng.pdf (Accessed on April 2016).
3. th Edition. Available at http://www.diabetesatlas.org/(Accessed on May 2016).
4. Powers AC. Diabetes Mellitus. In:Longo DL, Fauci AS, Kasper DL, eds. Harrison’s Principles of Internal Medicine. 18th edition. New York (NY):McGraw-Hill; 2012. p. 2275–2304.
5. Singh N, Armstrong DG, Lipsky BA., Preventing foot ulcers in patients with diabetes. Jama. 2005;293:217–228.
6. Nelson EA, O’Meara S, Craig D, et al. A series of systematic reviews to inform a decision analysis for sampling and treating infected diabetic foot ulcers. Health Technol Assess. 2006;10:iii-iv,ix-x, 1-221.
7. Hobizal KB, Wukich DK. Diabetic foot infections:current concept review. Diabetic Foot & Ankle. 2012;3:10.3402/dfa.v3i0.18409.
8. Redekop WK, Koopmanschap MA, Stolk RP, et al. Health-related quality of life and treatment satisfaction in Dutch patients with type 2 diabetes. Diabetes Care. 2002;25:458–463.
9. Coffey JT, Brandle M, Zhou H, et al. Valuing health-related quality of life in diabetes. Diabetes Care. 2002;25:2238–2243.
10. Gopalakrishnan S, Ganeshkumar P. Systematic Reviews and Meta-analysis:understanding the best evidence in primary healthcare. J Fam Med Prim Care. 2013;2:9–14.
11. Khan KS, Kunz R, Kleijnen J, et al. Five steps to conducting a systematic review. J R Soc Med. 2003;96:118–121.
12. Centre for Reviews and Disseminations. Systematic Reviews. CRD’s guidance for undertaking reviews in health care. University of York, 2009. Available at https://www.york.ac.uk/media/crd/Systematic_Reviews.pdf (Accessed on May 2016).
13. Economist Intelligence Unit. Foresight 2020. Economic, industry and corporate trends. The Economist Intelligence Unit, 2006. Available at http://graphics.eiu.com/files/ad_pdfs/eiuForesight2020_WP.pdf (Accessed on March 2016).
14. Organisation for Economic Co-operation and Development. OECD Data. purchasing power parities (PPP). Available at https://data.oecd.org/conversion/purchasing-power-parities-ppp.htm (Accessed on April 2016).
15. Prompers L, Huijberts M, Schaper N, et al. Resource utilisation and costs associated with the treatment of diabetic foot ulcers Prospective data from the Eurodiale Study. Diabetologia. 2008;51:1826–1834.
16. Girod I, Valensi P, Laforet C, et al. An economic evaluation of the cost of diabetic foot ulcers:results of a retrospective study on 239 patients. Diabetes Metabol. 2003;29:269–277.
17. Kerr M, Rayman G, Jeffcoate WJ. Cost of diabetic foot disease to the National Health Service in England. Diabet Med. 2014;31:1498–1504.
18. Craig J, Shenton R, Smith A. Economic analysis of soft-heel casting for diabetic foot ulcer:prevention and treatment. J Wound Care. 2013;22:44–48.
19. Abidia A, Laden G, Kuhan G, et al. The role of hyperbaric oxygen therapy in ischaemic diabetic lower extremity ulcers:a double-blind randomised-controlled trial. Eur J Vasc Endovasc Surg. 2003;25:513–518.
20. Van Acker K, Oleen-Burkey M, De Decker L, et al. Cost and resource utilization for prevention and treatment of foot lesions in a diabetic foot clinic in Belgium. Diabetes Res Clin Pract. 2000;50:87–95.
21. Gooday C, Hallam C, Sieber C, et al. An antibiotic formulary for a tertiary care foot clinic:admission avoidance using intramuscular antibiotics for borderline foot infections in people with diabetes. Diabet Med. 2013;30:581–589.
22. Tennvall GR, Apelqvist J, Eneroth M. Costs of deep foot infections in patients with diabetes mellitus. Pharmacoeconomics. 2000;18:225–238.
23. Hoffmann F, Claessen H, Morbach S, et al. Impact of diabetes on costs before and after major lower extremity amputations in Germany. J Diabetes Complications. 2013;27:467–472.
24. Happich M, John J, Stamenitis S. The quality of life and economic burden of neuropathy in diabetic patients in Germany in 2002–results from the Diabetic Microvascular Complications (DIMICO) study. Diabetes Res Clin Pract. 2008;81:223–230.
25. Smith D, Cullen MJ, Nolan JJ. The cost of managing diabetic foot ulceration in an Irish hospital. Ir J Med Sci. 2004;173:89–92.
26. Søndergaard LN, Christensen AB, Vinding AL, et al. Elevated costs and high one-year mortality in patients with diabetic foot ulcers after surgery. Dan Med J. 2015;62:A5050.
27. Persson U, Willis M, Odegaard K, et al. The cost-effectiveness of treating diabetic lower extremity ulcers with becaplermin (Regranex):a core model with an application using Swedish cost data. Value Health. 2000;3:39–46.
28. Ghatnekar O, Persson U, Willis M, et al. Cost effectiveness of Becaplermin in the treatment of diabetic foot ulcers in four European countries. Pharmacoeconomics. 2001;19:767–778.
29. Redekop WK, McDonnell J, Verboom P, et al. The cost effectiveness of Apligraf treatment of diabetic foot ulcers. Pharmacoeconomics. 2003;21:1171–1183.
30. Allenet B, Parée F, Lebrun T, et al. Cost-effectiveness modeling of Dermagraft for the treatment of diabetic foot ulcers in the french context. Diabetes Metab. 2000;26:125–132.
31. Whitehead SJ, Forest-Bendien VL, Richard JL, et al. Economic evaluation of Vacuum Assisted Closure® Therapy for the treatment of diabetic foot ulcers in France. Int Wound J. 2011;8:22–32.
32. Sotto A, Richard JL, Combescure C, et al. Beneficial effects of implementing guidelines on microbiology and costs of infected diabetic foot ulcers. Diabetologia. 2010;53:2249–2255.
33. Habacher W, Rakovac I, Görzer E, et al. A model to analyse costs and benefit of intensified diabetic foot care in Austria. J Eval Clin Pract. 2007;13:906–912.
34. Jansen JP, Kumar R, Carmeli Y. Accounting for the development of antibacterial resistance in the cost effectiveness of ertapenem versus piperacillin/tazobactam in the treatment of diabetic foot infections in the UK. Pharmacoeconomics. 2009;27:1045–1056.
35. Harrington C, Zagari MJ, Corea J, et al. A cost analysis of diabetic lower-extremity ulcers. Diabetes Care. 2000;23:1333–1338.
36. Carls GS, Gibson TB, Driver VR, et al. The economic value of specialized lower-extremity medical care by podiatric physicians in the treatment of diabetic foot ulcers. J Am Podiatr Med Assoc. 2011;101:93–115.
37. Rice JB, Desai U, Cummings AK, et al. Burden of diabetic foot ulcers for medicare and private insurers. Diabetes Care. 2014;37:651–658.
38. Sibbald RG, Torrance G, Hux M, et al. Cost-effectiveness of becaplermin for nonhealing neuropathic diabetic foot ulcers. Ostomy Wound Manage. 2003;49:76–84.
39. Kantor J, Margolis DJ. Treatment options for diabetic neuropathic foot ulcers:a cost-effectiveness analysis. Dermatol Surg. 2001;27:347–351.
40. Lavery LA, Boulton AJ, Niezgoda JA, et al. A comparison of diabetic foot ulcer outcomes using negative pressure wound therapy versus historical standard of care. Int Wound J. 2007;4:103–113.
41. Apelqvist J, Armstrong DG, Lavery LA, et al. Resource utilization and economic costs of care based on a randomized trial of vacuum-assisted closure therapy in the treatment of diabetic foot wounds. Am J Surg. 2008;195:782–788.
42. Tallis A, Motley TA, Wunderlich RP, et al. Clinical and economic assessment of diabetic foot ulcer debridement with collagenase:results of a randomized controlled study. Clin Ther. 2013;35:1805–1820.
43. Chuck AW, Hailey D, Jacobs P, et al. Cost-effectiveness and budget impact of adjunctive hyperbaric oxygen therapy for diabetic foot ulcers. Int J Technol Assess Health Care. 2008;24:178–183.
44. Amir L. Managing chronic conditions:economic analysis can help mitigate costs of diabetic ulcers. Healthc Financ Manage. 2014;68:90–94,96.
45. Horswell RL, Birke JA, Patout CA, Jr. A staged management diabetes foot program versus standard care:a 1-year cost and utilization comparison in a state public hospital system. Arch Phys Med Rehabil. 2003;84:1743–1746.
46. Gilligan AM, Waycaster CR, Landsman AL. Wound closure in patients with DFU:a cost-effectiveness analysis of two cellular/tissue-derived products. J Wound Care. 2015;24:149–156.
47. Gilligan AM, Waycaster CR, Motley TA. Cost-effectiveness of becaplermin gel on wound healing of diabetic foot ulcers. Wound Repair Regen. 2015;23:353–360.
48. Hutton DW, Sheehan P. Comparative effectiveness of the SNaP™ Wound Care System. Int Wound J. 2011;8:196–205.
49. Flack S, Apelqvist J, Keith M, et al. An economic evaluation of VAC therapy compared with wound dressings in the treatment of diabetic foot ulcers. J Wound Care. 2008;17:71–78.
50. Dougherty EJ. An evidence-based model comparing the cost-effectiveness of platelet-rich plasma gel to alternative therapies for patients with nonhealing diabetic foot ulcers. Adv Skin Wound Care. 2008;21:568–575.
51. O’Brien JA, Patrick AR, Caro JJ. Cost of managing complications resulting from type 2 diabetes mellitus in Canada. BMC Health Serv Res. 2003;3:7.
52. Stockl K, Vanderplas A, Tafesse E, et al. Costs of lower-extremity ulcers among patients with diabetes. Diabetes Care. 2004;27:2129–2134.
53. Davis WA, Norman PE, Bruce DG, et al. Predictors, consequences and costs of diabetes-related lower extremity amputation complicating type 2 diabetes:the Fremantle Diabetes Study. Diabetologia. 2006;49:2634–2641.
54. Hicks CW, Selvarajah S, Mathioudakis N, et al. Trends and determinants of costs associated with the inpatient care of diabetic foot ulcers. J Vasc Surg. 2014;60:1247-54,1254.e1-2.
55. Gordois A, Scuffham P, Shearer A, et al. The health care costs of diabetic peripheral neuropathy in the US. Diabetes Care. 2003;26:1790–1795.
56. Sargen MR, Hoffstad O, Margolis DJ. Geographic variation in Medicare spending and mortality for diabetic patients with foot ulcers and amputations. J Diabetes Complications. 2013;27:128–133.
57. Belatti DA, Phisitkul P. Declines in lower extremity amputation in the US Medicare population, 2000-2010. Foot Ankle Int. 2013;34:923–931.
58. Gil J, Schiff AP, Pinzur MS. Cost comparison:limb salvage versus amputation in diabetic patients with charcot foot. Foot Ankle Int. 2013;34:1097–1099.
59. Shobhana R, Rao PR, Lavanya A, et al. Foot care economics-cost burden to diabetic patients with foot complications:a study from southern India. J Assoc Physicians India. 2001;49:530–533.
60. Kumpatla S, Kothandan H, Tharkar S, et al. The costs of treating long-term diabetic complications in a developing country:a study from India. J Assoc Physicians India. 2013;61:102–109.
61. Habib SH, Biswas KB, Akter S, et al. Cost-effectiveness analysis of medical intervention in patients with early detection of diabetic foot in a tertiary care hospital in Bangladesh. J Diabetes Complications. 2010;24:259–264.
62. Siriwardana HD, Weerasekera D. The cost of diabetic foot conditions. Ceylon Med J. 2007;52:89–91.
63. Rerkasem K, Kosachunhanun N, Tongprasert S, et al. A multidisciplinary diabetic foot protocol at Chiang Mai University Hospital:cost and quality of life. Int J Low Extrem Wounds. 2009;8:153–156.
64. Benotmane A, Mohammedi F, Ayad F, et al. Management of diabetic foot lesions in hospital:costs and benefits. Diabetes Metab. 2001;27:688–694.
65. Ogbera AO, Fasanmade O, Ohwovoriole AE, et al. An assessment of the disease burden of foot ulcers in patients with diabetes mellitus attending a teaching hospital in Lagos, Nigeria. Int J Low Extrem Wounds. 2006;5:244–249.
66. Rezende KF, Ferraz MB, Malerbi DA, et al. Predicted annual costs for inpatients with diabetes and foot ulcers in a developing country-a simulation of the current situation in Brazil. Diabet Med. 2010;27:109–112.
67. Cawich SO, Islam S, Hariharan S, et al. The economic impact of hospitalization for diabetic foot infections in a Caribbean nation. Perm J. 2014;18:e101–4.
68. Ali SM, Fareed A, Humail SM, et al. The personal cost of diabetic foot disease in the developing world–a study from Pakistan. Diabet Med. 2008;25:1231–1233.
69. Wang A, Xu Z, Mu Y, et al. Clinical characteristics and medical costs in patients with diabetic amputation and nondiabetic patients with nonacute amputation in central urban hospitals in China. Int J Low Extrem Wounds. 2014;13:17–21.
70. Zimmet PZ, Kelly West Lecture 1991. Challenges in diabetes epidemiology–from West to the rest. Diabetes Care. 1992;15:232–252.
71. Mason J, O’Keeffe C, McIntosh A, et al. A systematic review of foot ulcer in patients with Type 2 diabetes mellitus. I:prevention. Diabet Med. 1999;16:801–812.
72. Mason J, O’Keeffe C, Hutchinson A, et al. A systematic review of foot ulcer in patients with Type 2 diabetes mellitus. II:treatment. Diabet Med. 1999;16:889–909.
73. Habacher W, Rakovac I, Görzer E, et al. A model to analyse costs and benefit of intensified diabetic foot care in Austria. J Eval Clin Pract. 2007;13:906–912.
74. Li R, Zhang P, Barker LE, et al. Cost-effectiveness ofinterventions to prevent and control diabetes mellitus:a systematic review. Diabetes Care. 2010;33(8):1872–1894.
75. Ortegon MM, Redekop WK, Niessen LW. Cost effectiveness of prevention andtreatment of the diabetic foot:a Markov analysis. Diabetes Care. 2004;27(4):901–907.
76. Driver VR, Fabbi M, Lavery LA, et al. The costs of diabetic foot:theeconomic case for the limb salvage team. J Vasc Surg. 2010;52(Suppl 3):17S–22S.